A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer

Summary

The study is being performed to assess the MTD, pharmacokinetics (PK), safety, tolerability and preliminary antitumor activity of DBPR112 in patients with head and neck cancer and EGFR mutated lung cancer.

Timeline

Start

2017-07-18

Primary completion

2018-08-04

Completion

2018-08-04

Outcome

Outcome not reported

Stopped (Business): “No more funding”

Drugs

Indications